AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04260438
Drug: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration under fed condition
Trial: NCT04260438
Drug: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration under fed condition
Trial: NCT00106392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00405886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets, duration: 16 weeks
Trial: NCT00742924
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01047501
Drug: AMR101 (ethyl icosapentate) - 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
Trial: NCT01047501
Drug: AMR101 (ethyl icosapentate) - 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
Trial: NCT01047501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 4 capsules/day for 12 weeks
Trial: NCT03342690
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions.
Trial: NCT00742924
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT00742924
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00742924
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT05537194
Drug: dihydropyridine calcium channel inhibitors use
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of dihydropyridine calcium channel inhibitors
Trial: NCT01762930
Drug: Shanchol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
Trial: NCT02272634
Drug: YPL-001 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily \[BID\]
Trial: NCT02272634
Drug: YPL-001 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily \[BID\]
Trial: NCT02272634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily \[BID\]
Trial: NCT03821870
Drug: Experimental drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second line treatment based on drug sensitivity analysis
Trial: NCT02737748
Drug: TWB-103 Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Trial: NCT02737748
Drug: Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Trial: NCT02196701
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate was provided as 2.5 mg tablets for oral administration.
Trial: NCT00643565
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT01283594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White-coated, modified-oval placebo tablets.
Trial: NCT01283594
Drug: Levodopa (L-dopa)
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
Trial: NCT04373044
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Po
Trial: NCT01704794
Drug: Folic Acid + Paludrine + Jobelyn (250mg)
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard routine drugs for treatment of SCD with 250mg Jobelyn
Trial: NCT03399292
Drug: Cationorm MD sine eye drops
RxNorm normalized name: tetrahydrozoline hydrochloride Ophthalmic Solution [Eye-Sine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: studyparticipants receive lipidbased eye drops once only in the study eye
Trial: NCT02755155
Drug: Human serum albumin infusion 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 15mL/kg of bodyweight over 24h/day
Trial: NCT02755155
Drug: Human serum albumin infusion 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
Trial: NCT01177410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules once daily for 12 weeks
Trial: NCT01056575
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC000459 100mg tablet, twice daily
Trial: NCT01688570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
Trial: NCT03809988
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (letrozole or fulvestrant)
Trial: NCT04559971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride for s.c. injection
Trial: NCT01099527
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose escalation of capecitabine, everolimus
Trial: NCT01197755
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT00620659
Drug: Comparator: MK0249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
Trial: NCT00620659
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
Trial: NCT04428333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline
Trial: NCT04428333
Drug: Fluorouracil (5FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil
Trial: NCT00658645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated tablets, orally, 12 weeks
Trial: NCT03038594
Drug: 0.09% Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01196676
Drug: AZD4451
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg capsules, 5 mg capsules, and 25 mg capsules
Trial: NCT01196676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg capsules, 5 mg capsules, and 25 mg capsules
Trial: NCT00278889
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion
Trial: NCT02171494
Drug: BMS Coumadin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00042458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
Trial: NCT02040779
Drug: Placebo breath-actuated inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
Trial: NCT02860221
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03265288
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
Trial: NCT03047798
Drug: Mouthrinse
RxNorm normalized name: NaFrinse 0.2% Mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.
Trial: NCT04059458
Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
Trial: NCT00367458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be administered placebo
Trial: NCT00866658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT00866658
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea if given, to be continued at a stable dose.
Trial: NCT02390687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Trial: NCT00742066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose tablet orally
Trial: NCT00824616
Drug: MK-0941
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
Trial: NCT00824616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, taken 3 times daily.
Trial: NCT00577395
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet once a month for 12 months
Trial: NCT03427502
Drug: Bupivacaine-epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
Trial: NCT03427502
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT02245022
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
Trial: NCT00778024
Drug: fluoxetine HCL 40 mg capsules
RxNorm normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04199013
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
Trial: NCT01683838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02149108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00331240
Drug: placebo (artificial tears)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05808192
Drug: Immunosuppressive
RxNorm normalized name: Immunosuppressive acidic protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
Trial: NCT03368430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
Trial: NCT00183898
Drug: oxaliplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
Trial: NCT02064894
Drug: oral morphine and oral ibuprofen
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
Trial: NCT02064894
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral ibuprofen combine to a placebo is the active comparator
Trial: NCT00806286
Drug: CS7017 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
Trial: NCT00806286
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching CS-7017 tablets
Trial: NCT00179816
Drug: High-Dose Chemotherapy with Tandem PBSC Rescue.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
Trial: NCT02455050
Drug: Systane® Gel Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 drops of Systane® Gel Drops in each eye.
Trial: NCT02455050
Drug: Genteal® Lubricant Gel Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
Trial: NCT03257514
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral drug have the same shape of thiotacid tablet
Trial: NCT00631449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
Trial: NCT04505137
Drug: GMA301 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMA301 Injection administered as a single dose of 1500 mg
Trial: NCT04505137
Drug: GMA301 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMA301 Injection administered as a single dose of 2000 mg
Trial: NCT02161822
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 80mg qd for 5weeks
Trial: NCT00237783
Drug: individualized dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
Trial: NCT03633734
Drug: Sequential Treatment
RxNorm normalized name: TABLET, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
Trial: NCT01260519
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: unfractionated heparin 2000 unites
Trial: NCT02043587
Drug: DNR
RxNorm normalized name: Do Not Resuscitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
Trial: NCT02043587
Drug: VCR
RxNorm normalized name: VCR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages \>50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
Trial: NCT02043587
Drug: CTX
RxNorm normalized name: CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A
Trial: NCT02043587
Drug: Liposomal AraC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
Trial: NCT02043587
Drug: LCV
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
Trial: NCT02043587
Drug: AraC
RxNorm normalized name: Carac
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C
Trial: NCT02043587
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
Trial: NCT02141425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02008786
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
Trial: NCT02008786
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04645966
Drug: Scheduled Liquid Paracetamol (SLP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLP administration after primary vaccinations 1 and 2.
Trial: NCT04645966
Drug: Therapeutic Liquid Paracetamol (TLP)
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLP administration after primary vaccinations 1 and 2
Trial: NCT01020955
Drug: NutropinAq (GH) and Increlex (IGF-I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
Trial: NCT01020955
Drug: NutropinAq and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
Trial: NCT04425135
Drug: Pemetrixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2,D1,ivgtt, Q3w.
Trial: NCT03272464
Drug: INCB039110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib may work by stopping your tumor cells from living and growing.
Trial: NCT02640092
Drug: [18F]GTP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
Trial: NCT02730117
Drug: Anti-Bacterial Agents
RxNorm normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial agents deemed appropriate by physicians in the ICU